PD-020Age and RAS status to select patients with metastatic colorectal cancer (mCRC) for initial sequential versus combination therapy including fluoropyrimidines (FP), irinotecan (Iri) and bevacizumab (Bev): XELAVIRI- study. (20th June 2018) - Modest, D; von Weikersthal, L Fischer; Decker, T; Vehling-Kaiser, U; Uhlig, J; Schenk, M; Freiberg-Richter, J; Peuser, B; Denzlinger, C; Reddemann, C Peveling genannt; Graeven, U; Schuch, G; et al.